Market Research Logo

Posterior Uveitis - Pipeline Review, H2 2016

Posterior Uveitis - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Posterior Uveitis – Pipeline Review, H2 2016, provides an overview of the Posterior Uveitis (Ophthalmology) pipeline landscape.

Uveitis is swelling and irritation of the uvea, the middle layer of the eye. One of the types of uveitis is posterior uveitis. Symptoms include blurred vision, dark, floating spots in the vision, eye pain, redness of the eye and sensitivity to light. The predisposing factors include having an infection, an autoimmune or inflammatory disorder and history of eye injury. Treatment includes steroid eye drops, anti-inflammatory and antibiotic or antiviral medication.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Posterior Uveitis – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Posterior Uveitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Posterior Uveitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Posterior Uveitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 2, 2 and 3 respectively.Posterior Uveitis.

Posterior Uveitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:

Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Posterior Uveitis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Posterior Uveitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Posterior Uveitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Posterior Uveitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Posterior Uveitis (Ophthalmology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Posterior Uveitis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Posterior Uveitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Posterior Uveitis Overview
Therapeutics Development
Pipeline Products for Posterior Uveitis - Overview
Posterior Uveitis - Therapeutics under Development by Companies
Posterior Uveitis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Posterior Uveitis - Products under Development by Companies
Posterior Uveitis - Companies Involved in Therapeutics Development
Aciont Inc.
Neuroptis Biotech
Oculis ehf
pSivida Corp.
Regeneron Pharmaceuticals Inc
Sandoz International GmbH
Santen Pharmaceutical Co., Ltd.
Posterior Uveitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dexamethasone acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dexamethasone sodium phosphate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EYS-606 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fluocinolone acetonide SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NOP-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sarilumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sirolimus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Posterior Uveitis - Dormant Projects
Posterior Uveitis - Discontinued Products
Posterior Uveitis - Product Development Milestones
Featured News & Press Releases
Oct 04, 2016: Phase 3 trial of Medidur in Posterior Segment Uveitis Meets Enrollment Target
Aug 15, 2016: Topline Results from First Phase 3 Trial of pSividas Medidur Presented at ASRS Annual Meeting
Aug 09, 2016: Primary Endpoint Met in pSivida's Utilization Study of New Medidur Inserter with Smaller Diameter Needle
Jul 27, 2016: pSivida's Medidur Maintains Same High Statistical Significance in Primary Endpoint through 12 Months in First Phase 3 Trial (p Less Than 0.00000001)
Jul 14, 2016: Investigator-Sponsored Phase 2 Study Results Show pSivida’s Medidur Fully Controlled Uveitis for Two Years with No Recurrence of Disease While Visual Acuity Continued to Improve
May 02, 2016: pSividas Medidur for Posterior Uveitis Granted Orphan Drug Designation in Europe
Mar 15, 2016: Additional Favorable Six-Month Safety Results for pSividas Medidur for Posterior Uveitis
Dec 28, 2015: pSivida Plans Medidur EU Marketing Approval Application Based on Single Phase 3 Clinical Trial
Dec 22, 2015: pSivida Medidur Meets Primary Efficacy Endpoint in Phase 3 Trial: High Statistical Significance in Prevention of Recurrence of Posterior Uveitis
Sep 28, 2015: pSivida Announces NDA for Medidur Now Planned Using Six-Month Efficacy Data from Both Phase III Trials; FDA Concurs
May 19, 2015: pSivida Reports Positive IOP Safety Data in Phase III Trial of Medidur for Posterior Uveitis
Mar 26, 2015: pSivida Completes Targeted Enrollment of Phase III Trial of Medidur for Posterior Uveitis
Apr 15, 2013: Aciont To Present at ARVO 2013 Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Posterior Uveitis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Posterior Uveitis - Pipeline by Aciont Inc., H2 2016
Posterior Uveitis - Pipeline by Neuroptis Biotech, H2 2016
Posterior Uveitis - Pipeline by Oculis ehf, H2 2016
Posterior Uveitis - Pipeline by pSivida Corp., H2 2016
Posterior Uveitis - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016
Posterior Uveitis - Pipeline by Sandoz International GmbH, H2 2016
Posterior Uveitis - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Posterior Uveitis - Dormant Projects, H2 2016
Posterior Uveitis - Discontinued Products, H2 2016
List of Figures
Number of Products under Development for Posterior Uveitis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report